Apparent argatroban resistance in a patient with elevated factor VIII levels

Annals of Pharmacotherapy

Volumn 47, Issue 7-8, 2013, Pages

  Kennedy, Dina M ^a   Alaniz, Cesar ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; BLOOD CLOTTING FACTOR 8; FONDAPARINUX; HEPARIN; PROTEIN C; PROTEIN S; SEROTONIN; WARFARIN;

ADULT; ANASTOMOSIS; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING DISORDER; BRAIN BIOPSY; BRAIN DISEASE; BRAIN EDEMA; BRAIN THIRD VENTRICLE; CASE REPORT; CONFUSION; CRANIOTOMY; DECOMPRESSIVE CRANIECTOMY; DEEP VEIN THROMBOSIS; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG INFUSION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HORMONE DETERMINATION; HUMAN; INTRACRANIAL HYPERTENSION; LEUKOCYTE COUNT; LUNG EMBOLISM; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SEROTONIN RELEASE; SIDE EFFECT; STEADY STATE; SUBDURAL HEMATOMA; THROMBOCYTE COUNT; THROMBOSIS; TREATMENT DURATION;

ANTICOAGULANTS; DRUG RESISTANCE, NEOPLASM; FACTOR VIII; FEMALE; HEPARIN; HUMANS; MIDDLE AGED; PIPECOLIC ACIDS; PLATELET AGGREGATION INHIBITORS; PROTHROMBIN TIME; THROMBOCYTOPENIA;

EID: 84880049812     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R745     Document Type: Article

References (10)

1. Product information. Acova (argatroban). Research Triangle Park, NC: GlaxoSmithKline, April 2012.
2. Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis. American College of Chest Physicians evidence-based clinical practice guidelines (9th edition). Chest 2012;141:495S-530S. doi: 10.1378/chest.11-2303
3. Francis JL, Hursting MJ. Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents. Blood Coagul Fibrinolysis 2005;16:251-7.
4. Uprichard J, Manning RA, Laffan MA. Monitoring heparin anticoagulation in the acute phase response. Br J Haematol 2010;149:613-9. doi: 10.1111/j.1365-2141.2010.08129.x
5. Hellwig TR, Peitz GJ, Gulseth MP. High-dose argatroban for treatment of heparin-induced thrombocytopenia with thrombosis: a case report and review of laboratory considerations. Am J Health Syst Pharm 2012;69: 190-5. doi: 10.2146/ajhp110147
6. Koster A, Fischer K, Harder S, et al. The direct thrombin inhibitor argat-ro ban: a review of its use in patients with and without HIT. Biologics 2007;1:105-12.
7. Warkentin TE. HIT paradigms and paradoxes. J Thromb Haemost 2011; 9:105-17. doi: 10.1111/j.1538-7836.2011.04322.x
8. Curvers J, van de Kerkhof D, Stroobants AK, et al. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful? Am J Clin Pathol 2012;138:551-8. doi: 10.1309/AJCPQOD9WFPEYY0H
9. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343:457-62. doi: 10.1136/jnnp.2006.103465
10. Tichelaar V, Mulder A, Kluin-Nelemans H, et al. The acute phase reaction explains only a part of initially elevated factor VIII:C levels: a prospective cohort study in patients with venous thrombosis. Thromb Res 2012;129:183-6. doi: 10.1016/j.thromres.2011.09.024